CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Galaxy Biomedical Investment Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Galaxy Biomedical Investment Co Ltd
Comprehensive Office Building
Yinhe Software Technology Park
Phone: +86 7793202636p:+86 7793202636 BEIHAI, GUX  536000  China Fax: +86 7793926916f:+86 7793926916
This company is no longer actively traded on any major stock exchange.
Business Summary
Galaxy Biomedical Investment Co Ltd, formerly Beihai Yinhe Industry Investment Co., Ltd., is a China-based company principally engaged in biomedical business. The Company mainly operates through three business segments. Biomedical segment is mainly engaged in the research and development of innovative drugs, model animal construction, tumor immune cell therapy and the development of stem cell technology. Electricity Transmission and Distribution segment is mainly engaged in the manufacture and sale of transformer products in various specifications and types. Electronic segment mainly provides various types of displacement sensors, brake resistance boxes, radio frequency (RF) components, resistors and potentiometers, among others. The Company distributes its products mainly in domestic market, with eastern China as its main market.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202312/31/2022Yes----

Industries
SIC Code Description
3613 Switchgear and switchboard apparatus
3699 Electrical machinery, equipment, and supplies, not elsewhere classified
3679 Electronic components, not elsewhere classified
7373 Computer integrated systems design
7371 Computer programming services
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board KeyangLiu 11/3/2022 11/3/2022
Chief Executive Officer JianHuang 11/3/2022 11/3/2022
Chief Financial Officer WeiboSong 48 10/18/2022 10/18/2022
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 2,031 (As of 12/31/2022)
Outstanding Shares: 1,099,911,762 (As of 5/8/2023)
Shareholders: 47,000
Stock Exchange: SHE
Fax Number: +86 7793926916


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, October 30, 2024